Navigating Global Nicotine Regulations: A Country-by-Country Guide

The same nicotine product that's legal in London can get seized at customs in Sydney. Global nicotine regulation is not converging. It is fragmenting, and the pace of that fragmentation is accelerating. In the two years to August 2026 the UK passed a new tobacco and vapes act, Australia closed every remaining legal route to nicotine pouches, France and the Netherlands prohibited oral nicotine products outright, Denmark capped pouch strength, and Brazil reaffirmed its vaping ban rather than lifting it. If you are manufacturing for international markets, you need granular knowledge of what each country requires before you commit to a formulation, a supplier, or a launch timeline.

This is not a policy opinion piece. It is a practical reference for manufacturers, brand owners, and procurement teams who need to move product across borders without running into regulatory walls.

How to read this guide. Every regulatory status below links to the regulator, gazette or statute it comes from, and every section carries the date it was last checked. Nicotine rules change on a scale of months, not years, so treat this as a point-in-time reference rather than a maintained compliance database. Confirm current status with local counsel before you commit budget to a market.

United States: PMTA or Nothing

Status as of August 2026.

The FDA's Center for Tobacco Products (CTP) regulates all tobacco and nicotine products under the Family Smoking Prevention and Tobacco Control Act (TCA). The US is the single most documentation-intensive market in the world for nicotine products.

• Market authorization: A Premarket Tobacco Product Application (PMTA) is required for every new tobacco or nicotine product. No marketing order, no legal sales. Period. The FDA publishes every order it grants in its tobacco products marketing orders list.
• Synthetic nicotine: Regulated since 14 April 2022, when an amendment carried in the Consolidated Appropriations Act, 2022 extended the statutory definition of "tobacco product" to cover nicotine from any source. The FDA sets out the scope on its non-tobacco nicotine page. The loophole that let synthetic nicotine products bypass FDA oversight is closed.
• Documentation bar: The FDA expects extensive ingredient characterization, manufacturing process documentation, stability data, toxicological assessments, and population-level health impact modeling. Your nicotine supplier's documentation quality directly affects application strength. Incomplete COAs or missing batch traceability records have tanked otherwise solid submissions.
• Enforcement reality: In January 2025 the FDA updated Import Alerts 98-06 and 98-07 so that any unauthorized e-cigarette entering the US may be detained without physical examination and refused admission. In May 2026 it finalized guidance on enforcement priorities for unauthorized ENDS and nicotine pouch products. Warning letters, injunctions and civil money penalties are logged in the FDA's public enforcement action database, which is the only count worth quoting. Customs and Border Protection cooperates directly with CTP on enforcement.
• Nicotine pouches: No longer a pending question. The FDA authorized 20 ZYN pouch products in January 2025, the first oral nicotine pouches cleared for the US market, then six on! PLUS products in December 2025 under a dedicated pouch review pilot. In June 2026 it went further and granted modified risk tobacco product orders for those 20 ZYN products, the first reduced-risk claim ever authorized for a pouch. On 4 August 2026 it authorized four more on! products through the same pilot. The FDA maintains the running list of authorized pouch products, which stood at 32 products from two manufacturers when we checked it on 19 August 2026. Pouches are treated as tobacco products and go through the same PMTA pathway as everything else.

The practical takeaway: if your nicotine source and its documentation can survive PMTA scrutiny, it can support submissions in virtually any other jurisdiction. The US sets the global ceiling for regulatory documentation requirements.

European Union: TPD Framework

Status as of August 2026.

The Tobacco Products Directive (Directive 2014/40/EU) provides harmonized rules across 27 member states, but "harmonized" is doing heavy lifting in that sentence.

• Nicotine concentration limit: 20 mg/mL maximum for consumer e-liquids, set by Article 20 of the directive.
• Volume limits: 10 mL maximum for refill containers, 2 mL for cartridges and tanks.
• Market entry: Six-month pre-market notification to each member state's competent authority via the EU-CEG (Common Entry Gate) system. You must submit separately for every country where you intend to sell.
• Ingredient reporting: Full quantitative listing of all ingredients, including nicotine grade, source, and purity data. Toxicological and emissions data required.
• Nicotine pouches: Not covered by the TPD, which predates the category. This is the single biggest source of regulatory divergence within the EU, and the divergence now runs from permissive to prohibited. Sweden regulates pouches under a dedicated 2022 act on tobacco-free nicotine products, separate from its tobacco law. Denmark never banned them: it capped them. Under the 2024 amending act, from 1 April 2026 a single pouch may contain no more than 9.0 mg of nicotine, only tobacco and menthol or mint flavours may be sold, and packs must be standardized, as the Danish Safety Technology Authority sets out for traders. The Netherlands has run a total sales ban since 1 January 2025. France prohibited oral nicotine products by Décret n° 2025-898 of 5 September 2025, in force from 1 April 2026; the Conseil d'État suspended part of that decree covering manufacture and export in December 2025 while leaving the sale ban standing, and on 13 July 2026 it referred the question of prohibiting production for export to the Court of Justice of the European Union and stayed the French cases until the Court answers, so the sale ban is settled and the production question is not. Manufacturers targeting multiple EU markets for pouches need country-specific legal review, market by market.
• TPD revision: Still not law, and still not even a proposal. The Commission published its evaluation of the EU tobacco control framework on 2 April 2026 and ran a public consultation on revising the tobacco products and advertising rules that closed in August 2026. Expect a legislative proposal covering flavours, disposables and nicotine pouches, but nothing is enacted, and anything adopted still needs a transposition period. Plan for the direction, not the date.
• Tobacco taxation: Separately, the Commission proposed on 16 July 2025 to extend excise duty to e-liquids, nicotine pouches and other nicotine products (COM(2025) 580). It is a proposal requiring unanimity among member states, not a rule you can price against yet.

Using EP-compliant nicotine simplifies the notification process significantly, as it aligns with the pharmacopoeial standards that EU regulators expect. Plan for the six-month notification lead time. It catches manufacturers off guard more often than the technical requirements do.

United Kingdom: New Act, Old Rules Still Running

Status as of August 2026.

The UK transposed EU TPD rules into domestic law post-Brexit and has now legislated its own framework on top of them.

• Tobacco and Vapes Act 2026: The bill received Royal Assent on 29 April 2026 and is now the Tobacco and Vapes Act 2026 (c. 18). It creates the generational sale ban on tobacco for anyone born on or after 1 January 2009, a retail licensing scheme, and broad powers over the sale, packaging, product standards and advertising of vaping and other nicotine products. Note the sequencing: the Act mostly confers powers. The specific product and advertising rules arrive in secondary legislation that is still to be made.
• Current product rules: Until that secondary legislation lands, day-to-day compliance still runs on Part 6 of the Tobacco and Related Products Regulations 2016. 20 mg/mL nicotine limit, 10 mL refill containers, 2 mL tanks, and MHRA notification of every product before sale, as the MHRA sets out for producers.
• Single-use vapes: Already banned. Selling or supplying single-use vapes has been illegal since 1 June 2025 under the Environmental Protection (Single-use Vapes) (England) Regulations 2024, with parallel regulations in the other UK nations. Compliant devices must be rechargeable and refillable.
• Nicotine pouches: Now squarely in scope. The 2026 Act's sale, distribution and advertising provisions cover nicotine products, not just tobacco and vapes, with the detail to follow in regulations.
• MHRA medicines pathway: Nicotine vaping products can be licensed as medicines through the Medicines and Healthcare products Regulatory Agency, and the licensing procedure is published. One e-cigarette was granted a UK marketing authorisation as a medicine back in 2015 but was never launched, and no licensed nicotine vaping medicine is on the market today. The route remains open for companies positioning products as cessation aids.
• Enforcement: Trading Standards and HMRC have significantly increased seizures of non-compliant vaping products, and the single-use ban gave them a second, simpler test to enforce at the border and in shops.

UK market entry remains straightforward if you are already TPD-compliant. The real question is what the secondary legislation under the 2026 Act will require. Manufacturers should build flexibility into their UK product lines.

Canada: Tightening Controls, With One Big Caveat

Status as of August 2026.

The Tobacco and Vaping Products Act (TVPA) governs the Canadian market, and the regulatory trajectory has been consistently more restrictive since 2020.

• Nicotine concentration limit: 20 mg/mL, under the Nicotine Concentration in Vaping Products Regulations (SOR/2021-123), in force 8 July 2021. The cap forced reformulation across brands that had built their Canadian business on high-strength products.
• Flavor restrictions: This is the row most guides get wrong. Federal flavour restrictions for vaping products are still a proposal, not law. The order restricting vaping flavours to tobacco, mint and menthol was published in Canada Gazette, Part I on 19 June 2021 and has never been finalized. Health Canada published a further notice of intent in 2025 and continues to list the measure as planned in its forward regulatory plan. Retail rules also vary by province and territory, so check provincial law separately rather than assuming the federal position is the whole picture.
• Reporting requirements: Product notification and periodic reporting under the Vaping Products Reporting Regulations (SOR/2023-123). Ingredient disclosure is mandatory.
• Nicotine pouches: Regulated as natural health products requiring a product licence, and since 28 August 2024 subject to the Supplementary Rules Respecting Nicotine Replacement Therapies Order (SOR/2024-169). In practice that means pharmacy-only sale from behind the counter, mint and menthol flavours only, a front-of-pack nicotine addiction warning, and tight advertising limits, as Health Canada announced when the measures came in. The product licence has to be in hand before any of that applies to you, and Health Canada publishes service standards for natural health product application reviews that vary by application class, so budget against the standard for your class rather than a rule of thumb.
• Import controls: All nicotine products need correct classification plus labelling that satisfies the Vaping Products Labelling and Packaging Regulations (SOR/2019-353) to clear the Canada Border Services Agency.

Canada is a case study in how quickly a permissive regulatory environment can tighten, and also in the difference between a proposed rule and a rule in force. Both matter. Do not over-invest in regulatory arbitrage, and do not reformulate against a draft as if it were law.

Australia: Pharmacy Channel Only, and Pouches Are Out

Status as of August 2026.

Australia has taken the most restrictive approach of any major English-speaking market. The Therapeutic Goods Administration (TGA) controls all nicotine product access, and the model changed substantially in 2024.

• Supply channel: Since 1 July 2024, only pharmacies may supply therapeutic vapes. Tobacconists, vape shops and convenience stores cannot.
• Prescription status: Vapes are no longer strictly prescription-only. Since 1 October 2024, a pharmacist may supply a vape with a nicotine concentration of 20 mg/mL or less to a person aged 18 or over without a prescription, subject to a pharmacist consultation and state or territory law. A prescription is still required above 20 mg/mL and for anyone under 18. The TGA sets out the model in its changes to the regulation of vapes guidance and the October 2024 media release.
• Product standards: Strengthened requirements for devices, ingredients, packaging and labelling were published in late 2024 and phased in through 2025. See the TGA's note on the new standards for nicotine vaping products.
• Import controls: The personal importation scheme for vapes has ceased. Disposable vapes have been banned from import since 1 January 2024, and since 1 March 2024 every other vape requires the importer to hold a licence and permit from the Office of Drug Control and to lodge a sponsor notification of compliance with the TGA before goods move. Only businesses can import.
• Nicotine pouches: Closed market. From 24 July 2026 there is no lawful consumer pathway to nicotine pouches in Australia at all. Personal importation, the Special Access Scheme, the Authorised Prescriber Scheme and pharmacy compounding have all been removed, retail sale is illegal, and the traveller's exemption no longer applies. See the TGA's nicotine pouches page and its media release on the new controls. Product imported anyway is seized and destroyed at the border.

Pharmaceutical-grade nicotine with complete TGA-compliant documentation is non-negotiable here. USP/EP-grade material with full analytical certificates, impurity profiles, and stability data is the minimum. Because supply runs through pharmacies, manufacturers building for Australia should look at whether nicotine salts or nicotine bitartrate dihydrate formulations better suit a therapeutic goods dossier than freebase does. For more on how salt forms compare to freebase, see our detailed comparison. What you should not do is build an Australian pouch line: that market is shut.

Japan: Heated Tobacco Dominates

Status as of August 2026.

Japan's regulatory structure created a unique market dynamic that has no parallel anywhere else in the world.

• Heated tobacco: Legal, mainstream, and the largest heated tobacco market in the world. Products are regulated as tobacco under the Tobacco Business Act, alongside the Act on Japan Tobacco Inc., which underpins Japan Tobacco's statutory position in the domestic industry. Category growth has not stalled: JT's FY2025 results report Ploom volume in Japan up 35 percent year on year.
• Nicotine e-liquids: Treated as pharmaceutical products under the Pharmaceuticals and Medical Devices Act. No nicotine e-liquid has obtained drug approval, so nicotine-containing e-liquids cannot be sold domestically. Japan publishes very little of this position in English, so confirm it with the Ministry of Health, Labour and Welfare directly before you build a plan around it.
• Non-nicotine e-liquids: Sold as ordinary consumer goods, creating a parallel market of zero-nicotine vaping products.
• Nicotine pouches: The market is emerging and the regulatory classification remains genuinely unsettled. Treat any pouch plan for Japan as requiring direct confirmation rather than an assumption.

If you are targeting Japan, heated tobacco products are the realistic pathway. The e-liquid market is effectively closed. Nicotine ingredient suppliers serving this market need to understand Japan Tobacco's role and the unique requirements of heated tobacco formulations.

India: Supply Source, Not Consumer Market

Status as of August 2026.

India occupies a paradoxical position in the global nicotine landscape.

• E-cigarettes: Banned under the Prohibition of Electronic Cigarettes Act, 2019. Production, manufacture, import, export, transport, sale, distribution, storage and advertisement are all prohibited. Penalties include imprisonment.
• Heated tobacco: Not a grey area, contrary to what a lot of market guides still say. The Act's definition of an electronic cigarette expressly covers heat-not-burn products, which places them inside the prohibition rather than outside it.
• Nicotine as an ingredient: The Act prohibits e-cigarettes and their components. It does not prohibit nicotine extracted from tobacco leaf as a chemical ingredient, and India remains a significant global source of it. Export is subject to ordinary foreign trade licensing rather than the Act, so verify any Indian supplier's export documentation and DGFT position yourself rather than taking it on trust.
• Oral nicotine and pouches: Status depends on a mix of central food and tobacco law and state-level prohibitions, and it is not uniform across the country. This is one to confirm state by state with local counsel before shipping anything.

India matters primarily as a supply source, not as a consumer market for finished nicotine products. Manufacturers sourcing from India should pay close attention to quality assurance certifications and traceability systems, as regulatory scrutiny of Indian-origin nicotine has increased in both the US and EU markets. The risks of working with unverified suppliers are particularly acute when sourcing from regions with less regulatory oversight of manufacturing practices.

Other Markets Worth Watching

Status as of August 2026.

• Brazil: Closed, not open. ANVISA did not lift its ban. RDC 855/2024, adopted on 23 April 2024 and effective from 2 May 2024, maintained the prohibition that has stood since 2009 and widened it to cover manufacture, transport, distribution and storage as well as sale, import and advertising. If your commercial plan assumed a Brazilian opening, it is wrong.
• New Zealand: The Smokefree Environments and Regulated Products Act still provides a comparatively permissive framework, but it is tightening. Single-use vaping devices have been prohibited since 17 June 2025 under the 2025 product safety amendment regulations. Retail is restricted to approved specialist vape retailers and other permitted outlets under the Ministry of Health's smokefree requirements.
• Saudi Arabia: Vaping products are legal and regulated. The Saudi Food and Drug Authority sets requirements for electronic nicotine delivery systems under technical regulation SFDA.FD 5005:2020, which governs product requirements and importer obligations.
• United Arab Emirates: Tobacco-free nicotine pouches are permitted through licensed channels under a Cabinet Resolution setting out a technical regulation for tobacco-free nicotine pouches, with conformity certification required before products can be placed on the market.
• South Korea: The definition of tobacco changed for the first time since 1988. An amendment to the Tobacco Business Act extending the legal definition to products made with nicotine, including synthetic nicotine, took effect on 24 April 2026. Synthetic nicotine e-liquids, previously sold as ordinary industrial products, now carry the same health warnings, advertising limits and smoke-free rules as any other tobacco product. Heated tobacco continues to hold significant share.

Building a Multi-Market Strategy

Six principles hold true across every market discussed here:

Start with dual-compliant nicotine. USP/EP-grade material with full certificates of analysis covers the broadest range of regulatory requirements. It is significantly cheaper to source one high-quality grade than to manage separate supply chains for each market. NicAlliance provides dual-compliant nicotine with documentation packages structured for multi-market submissions.

Let the strictest market set your floor. If you are selling in both the US and EU, build your documentation to PMTA standards. Every other market's requirements become a subset of what you have already prepared.

Assume markets can close, not only open. In the last two years Australia removed every legal route to nicotine pouches, France and the Netherlands prohibited oral nicotine, and Brazil restated a ban that plenty of forecasts had written off. Country risk in this category runs in both directions, and a market that closes strands inventory that a market that tightens merely reformulates.

Build formulation flexibility. Different markets favor different nicotine forms. The EU and UK lean toward freebase nicotine dilutions for e-liquids. The global pouch market increasingly uses nicotine bitartrate dihydrate for its stability advantages. Australia's pharmacy channel favors pharmacopoeial-grade salts. Having a supplier that offers multiple nicotine forms from a single qualified source simplifies everything.

Read the primary sources, and know what stage a rule is at. Subscribe to updates from the FDA's Center for Tobacco Products, the European Commission's tobacco pages, the Canada Gazette, the TGA, and legislation.gov.uk. Trade press routinely reports proposals as if they were law, which is exactly how Canada's unfinalized flavour order ended up in half the market guides on the internet. Check whether a rule is proposed, made, or in force before you act on it.

Factor in lead times. The EU's six-month notification, Canada's natural health product licensing timeline, and the multi-year PMTA process all mean that regulatory strategy must run well ahead of commercial launch plans. If you are planning a 2028 market entry, your regulatory work should already be underway.

Frequently Asked Questions